Formulation Development
NASAL DRUG DELIVERY - Overcoming the Challenges of Formulation Development
Eric Kaneps explores the nasal drug delivery landscape, including the benefits of nasal administration compared with other routes and the unique formulation challenges associated with this delivery method.
EXECUTIVE INTERVIEW - Salipro Biotech & Bio-Rad Laboratories: A Powerful Solution for Antibody Discovery Against Challenging Transmembrane Targets
Dr. Jens Frauenfeld, CEO, Salipro Biotech, and Dr. Francisco Ylera, R&D Team Lead at Bio-Rad Laboratories, explain how their collaboration is leveraging the Salipro® platform alongside Bio-Rad’s Pioneer™ Antibody Discovery Platform to target transmembrane proteins.
THERAPEUTIC FOCUS - Targeting Chronic Inflammation in Obesity
Johnny Peppers, PhD, and Christopher Mojcik, MD, PhD, explore the connection of obesity and inflammation, the current treatment landscape, and directions for future treatment.
DRUG DEVELOPMENT - The Next Frontier in Immunotherapy for Ovarian Cancer
Khursheed Anwer, PhD, MBA, and Douglas V. Faller, MD, PhD, highlight a new delivery system (TheraPlas®) being used to develop a more localized IL-12 immunotherapy for ovarian cancer and review its promising Phase 2 results.
EXECUTIVE INTERVIEW - Gelteq: A Breakthrough Ingestible Gel Drug & Nutrient Delivery System
Nathan Givoni, Co-Founder and CEO of Gelteq, discusses challenges with traditional drug delivery and the company’s innovative ingestible gel platform designed for drug and nutrient delivery.
Sitryx Nominates Novel Oral MTHFD2 Inhibitor for Clinical Development in Psoriatic Arthritis
Sitryx Therapeutics recently announced the nomination of SIT-047, a novel, oral MTHFD2 inhibitor, as the latest development candidate from its proprietary pipeline to progress to…
Opus Genetics Granted FDA Regenerative Medicine Advanced Therapy Designation for Gene Therapy Candidate
Opus Genetics, Inc. recently announced the US FDA has granted Regenerative Medicine Advanced Therapy (RMAT) designation to OPGx-LCA5, its investigational gene therapy for the treatment…
Palisade Bio Presents Positive Preclinical Data Highlighting Potential of PALI-2108 as a Promising Colon-Specific PDE4 Inhibitor for the Treatment of Ulcerative Colitis & Other Inflammatory Bowel Diseases
Palisade Bio, Inc. recently announced the presentation of positive preclinical data from PALI-2108, an orally administered, colon-specific phosphodiesterase-4 (PDE4) inhibitor prodrug in development for patients…
Vetter Prioritizes Continuity & Action in its Sustainability Efforts
Vetter published its fourth annual sustainability report. The report shows that the family-owned business is actively pursuing ambitious sustainability goals in climate protection, social responsibility,…
Aptar CSP Technologies Expands Service Offerings With Launch of cGMP Early Stage Clinical Manufacturing Site for Tablet & Capsule-Based Drug Products
Aptar CSP Technologies, part of AptarGroup, Inc. and a global leader in active material science solutions, announced the expansion of its service offerings with the…
Roquette Announces New Organization Following Acquisition of IFF Pharma Solutions
Roquette recently announced a new organization following the successful acquisition of IFF Pharma Solutions announced on May 1. The new organization is designed to enhance…
Can-Fite Has Raised $175 Million for the Development of Namodenoson & Piclidenoson
Can-Fite BioPharma Ltd. recently announced it has raised $175 million in funding to date. These funds have enabled the advancement of its lead drug candidates,…
Immutep’s Efti in Combination With KEYTRUDA Drives Strong Overall Survival in Head & Neck Cancer With CPS <1
Immutep Limited recently announced an excellent median Overall Survival (OS) of 17.6 months has been achieved in Cohort B of the TACTI-003 (KEYNOTE-C34) Phase IIb…
Moleculin Bolsters Annamycin Intellectual Property Portfolio With Granting of Two New U.S. Patents
Moleculin Biotech, Inc. recently announced the US Patent and Trademark Office (USPTO) has granted two additional US patents with claims covering Annamycin. US patent number…
Cell & Gene Therapy Market Set to Grow at 31.3% CAGR Through 2030
The global dermatological cell and gene therapy (CGT) market is poised for exceptional growth at a compound annual growth rate (CAGR) of 31.3%, with sales…
Roquette Completes the Acquisition of IFF Pharma Solutions
Roquette recently announced the successful completion of its acquisition of IFF Pharma Solutions. This strategic milestone marks a significant step forward in its ambition to…
Bespak Achieves Sustainability Milestone With First Life Cycle Assessment for Pressurized Metered Dose Inhaler Valve
Bespak, a specialist inhalation contract development and manufacturing organization (CDMO), recently announced it has completed its first life cycle assessment (LCA) for its market-leading BK357…
Crown Bioscience & NEXT Oncology Cement Partnership Extension
Crown Bioscience recently announced the extension of its partnership with NEXT Oncology, one of the world’s largest Phase I Oncology Clinical Trial networks. This strategic…
Actinogen Provides Pivotal Alzheimer’s Trial Enrolment Update & Other Business News
Actinogen Medical Limited recently announced its Alzheimer’s disease phase 2b/3 trial has now enrolled 60 participants and expects to reach 100 by the end of…
Vaxart Completes Enrollment in Phase 1 Trial for its Norovirus Oral Pill Vaccine Candidate
Vaxart, Inc. recently announced it completed enrollment of its Phase 1 clinical trial evaluating its second-generation oral norovirus vaccine constructs head-to-head against its first-generation constructs.…
